Hydroxychloroquine and a low antiresorptive activity bisphosphonate conjugate prevent and reverse ovariectomy-induced bone loss in mice through dual antiresorptive and anabolic effects  

作　　者：Zhenqiang Yao Akram Ayoub Venkatesan Srinivasan Jun Wu Churou Tang Rong Duan Aleksa Milosavljevic Lianping Xing Frank H.Ebetino Alison J.Frontier Brendan F.Boyce 

机构地区：[1]Department of Pathology and Laboratory Medicine,University of Rochester Medical Center,Rochester,NY 14642,USA [2]Department of Chemistry,University of Rochester,Rochester NY14627,USA [3]School of Arts and Sciences,University of Rochester,Rochester NY14627,USA [4]BioVinc,LLC,Pasadena,CA 91107,USA

出　　处：《Bone Research》2024年第3期734-744,共11页骨研究（英文版）

基　　金：funded by National Institutes of Health,National Institute on Aging,grant numbers,R01AG076731,R01AG049994;National Institute for Arthritis and Musculoskeletal and Skin Diseases,R01AR043510,and P30 AR069655。

摘　　要：Osteoporosis remains incurable.The most widely used antiresorptive agents,bisphosphonates(BPs),also inhibit bone formation,while the anabolic agent,teriparatide,does not inhibit bone resorption,and thus they have limited efficacy in preventing osteoporotic fractures and cause some side effects.

关 键 词：res CONJUGATE phosphonate 

分 类 号：R580[医药卫生—内分泌]